Company intelligence / Profile preview

China-Biotics

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

China-Biotics commercialized multiple probiotics-based products (capsules, tablets, bulk ingredients) for GI health, immunity, and women’s/senior health; no clinical trials for pharmaceutical indications reported. Largest Chinese probiotics plant commercialized in 2010. Retail operation closed in 2011, switched entirely to B2B bulk supply.

Therapeutic areas: Women's HealthGastroenterologyImmunology
Modalities: Live biotherapeutic product therapyMicrobial therapyProbiotics
Industry: Non-Drug Biotech

Partnerships

Bright Dairy & Food (supply agreement for probiotics additives)Lijia Pharmaceutical (supply agreement for probiotics-based supplements)US-based nutritional product company (first US customer partnership in 2011)

Beyond the preview

Go deeper on China-Biotics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on China-Biotics.

Explore the full profile